2410 — TYK Medicines Income Statement
0.000.00%
Last trade - 00:00- HK$4.60bn
- HK$4.36bn
- CNY0.11m
Annual income statement for TYK Medicines, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 44.2 | 0 | 0.107 |
| Cost of Revenue | |||
| Gross Profit | 20 | 0 | 0.014 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 341 | 361 | 375 |
| Operating Profit | -296 | -361 | -375 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -312 | -383 | -388 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -312 | -383 | -388 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | -311 | -382 | -387 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -311 | -382 | -387 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.839 | -1.01 | -0.97 |